Anacor Issues Update on Arbitration with Valeant, Says Prelim. Injunction Hearing Cancelled

By: Benzinga
Anacor Pharmaceuticals (NASDAQ: ANAC ) today announced that Valeant Pharmaceuticals International, Inc. (NYSE: VRX ), or Valeant, has agreed that the launch of efinaconazole, its topical product candidate for the treatment of onychomycosis, will not occur until after the September 2013 arbitration hearing to resolve our breach of contract dispute with Valeant. As
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.